GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, will release its fourth quarter and full year 2024 financial results on March 27, 2025, after the U.S. market closes. The company will follow the financial report with a live conference call and webcast at 4:30 p.m. ET to discuss its financial performance and provide a corporate update.
The company’s lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine that recently received a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial. Currently, GEO-CM04S1 is undergoing three Phase 2 clinical trials, focusing on specific patient populations including immunocompromised patients, those with chronic lymphocytic leukemia, and healthy patients who previously received mRNA vaccines.
In the oncology sector, GeoVax is evaluating Gedeptin®, a novel oncolytic solid tumor gene-directed therapy. The company has completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers and plans a Phase 2 clinical trial combining Gedeptin® with an immune checkpoint inhibitor for first recurrent head and neck cancer.
The upcoming conference call will provide investors and stakeholders an opportunity to gain insights into the company’s research progress, financial status, and potential future developments in vaccine and cancer therapy technologies. Participants can access the live conference call by registering in advance through the provided registration link.
GeoVax continues to demonstrate its commitment to developing innovative solutions for some of the world’s most challenging infectious diseases and cancer treatments, positioning itself as a potential significant contributor to medical advancements in these critical areas.
This news story relied on a press release distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax Prepares to Announce Fourth Quarter and Full Year 2024 Financial Results.